Revolutionize your cancer research and elevate minimal invasive cancer clinical management with our groundbreaking New Extracellular Vesicles Isolation Technology.

Captis Diagnostics helps academic research labs and commercial diagnostic labs on the basic and translational research on extracellular vesicles, and helps physician and oncologist on early cancer screening, diagnosis, treatment selection, treatment response monitoring and recurrence detection using our high performance extracellular vesicles isolation technology.

Game-changing Lipid Nanoprobe

What we’re good at?

Captis Diagnostics believes in our innovative nanomaterials and nanotechnologies for enriching the extracellular vesciles can help you achieve the best results for your cancer research and diagnosis.

Nanotechnologies Engineering

We developed patent protected extracellular vesicle (EV) isolation technology with isolation efficiency over 90% in plasma.

Diagnostic assay development

It's not enough to have EV isolation technology, you also need to have the right diagnostic assay/tools to analyze the EV cargo.

Our key technology for EVs isolation

1

Total EVs Capture

Over 90% EVs capture in plasma.

2

Simple workflow

One step in 15 minutes.

3

High Stability

Shelf-life over 8 months storage.

4

Downstream molecular analysis.

EVs harbor high molecular weight DNA&RNA and protein

Publications

[1] Wan Y, Cheng G, Liu X, et al. Rapid magnetic isolation of extracellular vesicles via lipid-based nanoprobes. Nature Biomedical Engineering 2017;1:0058.

[2] Wan Y, Maurer M, He H-Z, et al. Enrichment of extracellular vesicles with lipid nanoprobe functionalized nanostructured silica. Lab on a Chip 2019;19:2346-55.

[3] "R. A. Harouaka, M.-D. Zhou, Y.-T. Yeh, W. J. Khan, A. Das, X. Liu, C. C. Christ, D. T. Dicker, T. S. Baney, J. T. Kaifi, C. P. Belani, C. I. Truica, W. S. El-Deiry, J. P. Allerton, and S.-Y. Zheng, Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells, Clinical Chemistry, vol. 60, pp. 323-333, 2014."

[4] Yee NS, Zhang S, He H-Z, Zheng S-Y. Extracellular Vesicles as Potential Biomarkers for Early Detection and Diagnosis of Pancreatic Cancer. Biomedicines 2020;8.

[5] Milosevic J, Lu M, Greene W, He H-Z, Zheng S-Y. An Ultrafast One-Step Quantitative Reverse Transcription-Polymerase Chain Reaction Assay for Detection of SARS-CoV-2. Front Microbiol 2021;12:749783.

[6] A. Chopra, H. He, J. Milosevic, N. Tirukkovalur, R. El Asmar, I. Nassour, G. Nunns, M. Chen, J. Chen, S. Jiang, A.D. Singhi, A. Saeed, J.Y. Zhang, K.K. Lee, A.H. Zureikat, S.-Y. Jiang, A. Paniccia, KRAS mutations allelic frequency dynamics using plasma extracellular vesicles: Association with survival outcomes in localized pancreatic adenocarcinoma, Journal of Clinical Oncology 42(16_suppl) (2024) 4167-4167.

[7] H. He, J. Milosevic, S. Zheng, Abstract LB099: Identifying actionable genomic alterations in non-small cell lung cancer through the analysis of extracellular vesicles in plasma, Cancer Research 84(7_Supplement) (2024) LB099-LB099.

[8] S. Zhang, F. Wang, M. Chen, J. Kim, M. Lu, H. He, S. Zheng, Abstract 998: A blood-based extracellular vesicles DNA methylation signature for colorectal cancer screening, Cancer Research 83(7_Supplement) (2023) 998-998.